A novel infectious disease, caused by 2019 Novel Coronavirus (2019-nCoV) is responsible for the recent outbreak of severe respiratory disease. The 2019-nCoV spread rapidly and reaching epidemic proportions in many countries of the world. ACE2 was identified as a key receptor for 2019-nCoV infections. Excessive form of soluble ACE2 rescues cellular ACE2 activity which has a protective role in acute lung failure and neutralizes the virus. The short half-life of ACE2 is a major limitation to its practical application. Nanoparticle-based drug delivery systems are one of the most widely investigated approaches for developing novel therapies for a variety of diseases. Nevertheless, nanoparticles suffer from the rapid removal from the bloodstream by the reticuloendothelial system (RES). A noncovalent attachment of nanoparticles to RBCs increases their half-life in blood and allows transient accumulation in the lungs, while decreases their uptake by the liver and spleen. Connecting the recombinant ACE2 into the surface of nanoparticles that were attached to RBCs can be a potential therapeutic approach for 2019-nCoV infection through increasing their lung targeting to naturalize the virus and also acting as a bioreactor in the blood circulation to decrease serum level of Angiotensin II and protects lungs from injury/ARDS.

中文翻译：

---

通过红细胞搭便车输送重组 ACE2 治疗 2019-nCoV 感染的潜在假设

由 2019 新型冠状病毒 (2019-nCoV) 引起的一种新型传染病是最近爆发的严重呼吸道疾病的原因。2019-nCoV 迅速传播，在世界许多国家达到流行病的程度。ACE2 被确定为 2019-nCoV 感染的关键受体。过量的可溶性 ACE2 可以挽救细胞 ACE2 活性，从而在急性肺衰竭中发挥保护作用并中和病毒。ACE2的半衰期短是其实际应用的主要限制。基于纳米颗粒的药物递送系统是开发针对多种疾病的新疗法的最广泛研究的方法之一。然而，纳米粒子会被网状内皮系统（RES）从血流中快速清除。纳米颗粒与红细胞的非共价连接增加了它们在血液中的半衰期，并允许在肺部短暂积累，同时减少了它们被肝脏和脾脏的吸收。将重组 ACE2 连接到附着在红细胞上的纳米粒子表面，可以成为治疗 2019-nCoV 感染的潜在治疗方法，通过增加肺部靶向性来使病毒自然化，并充当血液循环中的生物反应器来降低血管紧张素的血清水平II 并保护肺部免受伤害/ARDS。